Hypodiploidy is a major prognostic factor in multiple myeloma
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Conventional karyotypes performed before any treatment in 208 patients with multiple myeloma were reviewed by the Groupe Français de Cytogénétique Hématologique. A total of 138 patients displayed complex chromosomal abnormalities (CCAs). According to the chromosome number pattern, a first group of 75 patients had a hyperdiploid karyotype. A second group of 63 patients referred to as the hypodiploid group had either pseudodiploid, hypodiploid, or near-tetraploid karyotypes. Of 159 treated patients available for survival analysis, 116 had an abnormal karyotype. The comparison of overall survival (OS) between hyperdiploid and hypodiploid patients showed a highly significant difference (median OS 33.8 vs 12.6 months, respectively, P < .001). The presence of 14q32 rearrangements (36 of 116 patients) worsened the prognosis (median OS 17.6 vs 29.9 months, P < .02). The presence of chromosome 13q abnormalities (13qA, 63 patients) did not modify OS in CCA patients (median OS 20.6 vs 27.8 months,P < .59). However, taking into account the whole series including normal karyotypes, 13qA (63 of 159 patients) had a significant impact on OS (median 20.6 vs 37.1 months,P < .04). In the same way, the presence of a hypodiploid karyotype (52 of 159 patients) had a strong prognostic value (OS 12.8 vs 44.5 months, P < .000 01). A multivariate analysis including stage, β2-microglobulin, bone marrow plasmocytosis, treatment type, 13qA, and hyperdiploidy and hypodiploidy showed that a hypodiploid karyotype was the first independent factor for OS (P < .001), followed by treatment approach. These results confirm that the chromosome number pattern of malignant plasma cells is a very powerful prognostic factor in newly diagnosed multiple myeloma patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,840
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Hallek, M., Leif Bergsagel, P., & Anderson, K. C. (1998) · Blood · doi:10.1182/blood.v91.1.3 · Cited by 752
Kyle, R. A., & Greipp, P. R. (1980) · New England Journal of Medicine · doi:10.1056/nejm198006123022405 · Cited by 452
Dewald, G., Kyle, R., Hicks, G., & Greipp, P. (1985) · Blood · doi:10.1182/blood.v66.2.380.380 · Cited by 401
Tricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S., Vesole, D., Naucke, S., & Sawyer, Jr. (1995) · Blood · doi:10.1182/blood.v86.11.4250.bloodjournal86114250 · Cited by 395
Bataille, R., & Harousseau, J.-L. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706053362307 · Cited by 389
Cytogenetic findings in 200 patients with multiple myeloma
Sawyer, J. R., Waldron, J. A., Jagannath, S., & Barlogie, B. (1995) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(94)00284-i · Cited by 343
Zojer, N., Königsberg, R., Ackermann, J., Fritz, E., Dallinger, S., Krömer, E., Kaufmann, H., Riedl, L., Gisslinger, H., Schreiber, S., et al. (2000) · Blood · doi:10.1182/blood.v95.6.1925 · Cited by 321
Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N. C., Anaissie, E., Spoon, D., et al. (2000) · Blood · doi:10.1182/blood.v95.12.4008 · Cited by 320
Greipp, P., Lust, J., O'Fallon, W., Katzmann, J., Witzig, T., & Kyle, R. (1993) · Blood · doi:10.1182/blood.v81.12.3382.3382 · Cited by 312
Lai, J., Zandecki, M., Mary, J., Bernardi, F., Izydorczyk, V, Flactif, M., Morel, P., Jouet, J., Bauters, F., & Facon, T. (1995) · Blood · doi:10.1182/blood.v85.9.2490.bloodjournal8592490 · Cited by 216
Drach, J. W., Schuster, J., Nowotny, H., Angerler, J., Rosenthal, F., Fiegl, M., Rothermundt, C. A., Gsur, A., Jaeger, U., & Heinz, R. (1995) · PubMed · Cited by 192
Predictive Role of Interphase Cytogenetics for Survival of Patients With Multiple Myeloma
Königsberg, R., Zojer, N., Ackermann, J., Krömer, E., Kittler, H., Fritz, E., Kaufmann, H., Nösslinger, T., Riedl, L., Gisslinger, H., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.804 · Cited by 182
Calasanz, M. J., Cigudosa, J. C., Odero, M. D., Ferreira, C., Ardanaz, M. T., Fraile, A., Carrasco, J. L., Solé, F. G., Cuesta, B., & Gullón, A. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199702)18:2<84::aid-gcc2>3.0.co;2-x · Cited by 175
Tricot, G., Sawyer, J. R., Jagannath, S., Desikan, K. R., Siegel, D., Naucke, S., Mattox, S., Bracy, D., Munshi, N., & Barlogie, B. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2659 · Cited by 172
Pérez-Simón, J. A., Garcı́a-Sanz, R., Tabernero, M. D., Almeida, J., González, M., Fernández-Calvo, J., Moro, M. J., Hernández, J. M., Miguel, J. F. S., & Orfão, A. (1998) · Blood · doi:10.1182/blood.v91.9.3366 · Cited by 169
Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases
Smadja, N.-V., Fruchart, C., Isnard, F., Louvet, C., Dutel, J.-L., Cheron, N., Grange, M.-J., Monconduit, M., & Bastard, C. (1998) · Leukemia · doi:10.1038/sj.leu.2401041 · Cited by 168
Self-citationMONOCLONAL GAMMOPATHIES OF UNDETERMINED SIGNIFICANCE
Kyle, R. A., & Rajkumar, S. V. (1999) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70120-9 · Cited by 167
MULTIPLE MYELOMA: ALMOST ALL PATIENTS ARE CYTOGENETICALLY ABNORMAL
Zandecki, M., Laï, J. L., & Facon, T. T. F. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.d01-2939.x · Cited by 148
Prognostic value of cytogenetics in multiple myeloma
Seong, C., Delasalle, K. B., Hayes, K. J., Weber, D., Dimopoulos, M. A., Swantkowski, J., Huh, Y. O., Glassman, A. B., Champlin, R. E., & Alexanian, R. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00657.x · Cited by 145
Rajkumar, S. V., Fonseca, R., Dewald, G. W., et al. (1999) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00009-6 · Cited by 101
The impact of the new FISH technologies on the cytogenetics of haematological malignancies
Kearney, L. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01181.x · Cited by 90
Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases
Fonseca, R., Witzig, T. E., Gertz, M. A., Kyle, R. A., Hoyer, J. D., Jalal, S. M., & Greipp, P. R. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00700.x · Cited by 88
Deletion of the retinoblastoma gene in multiple myeloma.
Dao, D., Sawyer, J. R., Epstein, J., Hoover, R. G., Barlogie, B., & Tricot, G. J. K. (1994) · PubMed · Cited by 84
Karyotype in multiple myeloma and plasma cell leukaemia
Weh, H. J., Gutensohn, K., Selbach, J., Kruse, R., Wacker-Backhaus, G., Seeger, D. R., Fiedler, W., Fett, W., & HOSSFELD, D. K. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90071-m · Cited by 84
DIAGNOSIS, PROGNOSIS, AND STANDARD TREATMENT OF MULTIPLE MYELOMA
Boccadoro, M., & Pileri, A. (1997) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70418-4 · Cited by 83
FLACTIF, M., Zandecki, M., Laï, J. L., et al. (1995) · PubMed · Cited by 83
Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients
García‐Sánz, R., ORFAO, A., González, M., et al. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb03387.x · Cited by 80
Taniwaki, M., Nishida, K., Takashima, T., Nakagawa, H., Fujii, H., Tamaki, T., Shimazaki, C., Horiike, S., Misawa, S., & Abe, T. (1994) · Blood · doi:10.1182/blood.v84.7.2283.2283 · Cited by 68
Why better prognostic factors for multiple myeloma are needed [editorial] [see comments]
Kyle, R. A. (1994) · Blood · doi:10.1182/blood.v83.7.1713.1713 · Cited by 54
Cited by
The molecular classification of multiple myeloma
Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., et al. (2006) · Blood · doi:10.1182/blood-2005-11-013458 · Cited by 1,133
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
Kyle, R. A., & Rajkumar, S. V. (2009) · Leukemia · doi:10.1038/leu.2008.291 · Cited by 1,121
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
“For example, multiple myeloma cells with t(14;16) translocation overexpress the transcription factor MAF, which not only transactivates the cyclin D2 promoter, thereby increasing multiple myeloma cell proliferation; but also upregulates β7-integrin expression, thereby promoting tumour cell adhesion to BMSCs28.”
BackgroundAvet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-040410 · Cited by 911
Multiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818
Metadata
- Authors
- Smadja, N. V., Bastard, C., Brigaudeau, C., Leroux, D., & Fruchart, C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2001-10-01
- Volume
- 98
- Issue
- 7
- Pages
- 2229-2238
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1993549070
- Cited by
- 390
- References
- 35
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.